Annexin Pharmaceuticals AB (publ) (STO:ANNX)

Sweden · Delayed Price · Currency is SEK

6.50

+0.24 (3.83%)

Nov 4, 2026, 9:00 AM CET

STO:ANNX Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	10.72	10.07	9.59	8.01	12.29	10.7
Research & Development	31.29	26.24	40.81	36.03	28.37	42.13
Operating Expenses	42.01	36.31	50.4	44.04	40.66	52.83
Operating Income	-42.01	-36.31	-50.4	-44.04	-40.66	-52.83
Interest Expense	-	-	-0.05	-	-0	-1.86
Interest & Investment Income	0.27	0.47	0.28	0.12	-	-
Earnings From Equity Investments	-	-	-	-	-	0.95
Currency Exchange Gain (Loss)	-0.33	-1.05	-0.08	-0.14	-0.07	1.59
Pretax Income	-42.08	-36.89	-50.25	-44.05	-40.73	-52.14
Net Income	-42.08	-36.89	-50.25	-44.05	-40.73	-52.14
Net Income to Common	-42.08	-36.89	-50.25	-44.05	-40.73	-52.14
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	7	7	5	2	1	1
Shares Outstanding (Diluted)	7	7	5	2	1	1
Shares Change	20.00%	46.31%	170.59%	14.23%	78.30%	33.40%
EPS (Basic)	-5.67	-5.58	-11.11	-26.36	-27.84	-63.55
EPS (Diluted)	-5.67	-5.58	-11.11	-26.36	-27.84	-63.55
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-41.22	-37.05	-50.23	-43.4	-41.17	-45.02
Free Cash Flow Per Share	-5.55	-5.60	-11.11	-25.97	-28.14	-54.88
EBITDA	-41.81	-36.12	-50.2	-43.85	-40.46	-52.63
D&A For EBITDA	0.19	0.19	0.19	0.19	0.19	0.19
EBIT	-42.01	-36.31	-50.4	-44.04	-40.66	-52.83